{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:43:22Z","timestamp":1778575402641,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001545","name":"Children's Tumor Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.cct.2022.106900","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T02:18:24Z","timestamp":1661480304000},"page":"106900","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Design of a randomized, placebo-controlled, phase 2 study evaluating the safety and efficacy of tanezumab for treatment of schwannomatosis-related pain"],"prefix":"10.1016","volume":"121","author":[{"given":"Jennifer L.W.","family":"Da","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa L.","family":"Merker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin T.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Ina","family":"Ly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alona","family":"Muzikansky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela L.","family":"Wolters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scot","family":"Styren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark T.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott R.","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2022.106900_bb0005","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/jnnp-2018-318538","article-title":"Schwannomatosis: a genetic and epidemiological study","volume":"89","author":"Evans","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.cct.2022.106900_bb0010","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00439-016-1753-8","article-title":"The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis","volume":"136","author":"Kehrer-Sawatzki","year":"2017","journal-title":"Hum. Genet."},{"key":"10.1016\/j.cct.2022.106900_bb0015","series-title":"GeneReviews((R)). Seattle (WA)","article-title":"Schwannomatosis","author":"Dhamija","year":"1993"},{"key":"10.1016\/j.cct.2022.106900_bb0020","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/bjd.14485","article-title":"CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic naevi and internal malignancies: a case series and review of the literature","volume":"175","author":"Sargen","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.cct.2022.106900_bb0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00401-021-02387-z","article-title":"DGCR8 and the six hit, three-step model of schwannomatosis","volume":"143","author":"Nogue","year":"2022","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cct.2022.106900_bb0030","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1634\/theoncologist.2012-0162","article-title":"Clinical features of schwannomatosis: a retrospective analysis of 87 patients","volume":"17","author":"Merker","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.cct.2022.106900_bb0035","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/ALN.0b013e31821b1ac5","article-title":"Antagonism of nerve growth factor-TrkA signaling and the relief of pain","volume":"115","author":"Mantyh","year":"2011","journal-title":"Anesthesiology"},{"key":"10.1016\/j.cct.2022.106900_bb0040","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/0092-8674(94)90378-6","article-title":"Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons","volume":"76","author":"Crowley","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.cct.2022.106900_bb0045","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0304-3959(95)00120-4","article-title":"Intraplantar injection of nerve growth factor into the rat hind paw: local edema and effects on thermal nociceptive threshold","volume":"64","author":"Amann","year":"1996","journal-title":"Pain"},{"key":"10.1016\/j.cct.2022.106900_bb0050","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/acn3.51386","article-title":"Transcriptomic signature of painful human neurofibromatosis type 2 schwannomas","volume":"8","author":"Kukutla","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.cct.2022.106900_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144620","article-title":"Immortalized human Schwann cell lines derived from tumors of Schwannomatosis patients","volume":"10","author":"Ostrow","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cct.2022.106900_bb0060","first-page":"2021","article-title":"Briefing document, joint meeting of arthritis advisory committee and drug safety and risk management advisory committee, BLA 761130 Tanezumab","volume":"24-25","author":"Administration FaD","year":"2021","journal-title":"March"},{"key":"10.1016\/j.cct.2022.106900_bb0065","series-title":"Presented at the Annual Congress of the European Society for Medical Oncology (ESMO), Paris, France, September 16\u201321","article-title":"Efficacy and safety of tanezumab in subjects with cancer pain predominantly due to bone metastasis receiving background opioid therapy","author":"Fallon","year":"2021"},{"key":"10.1016\/j.cct.2022.106900_bb0070","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/art.37950","article-title":"Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial","volume":"65","author":"Brown","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cct.2022.106900_bb0075","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jpain.2012.05.006","article-title":"Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial","volume":"13","author":"Brown","year":"2012","journal-title":"J. Pain"},{"key":"10.1016\/j.cct.2022.106900_bb0080","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1097\/j.pain.0000000000001928","article-title":"Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety","volume":"161","author":"Markman","year":"2020","journal-title":"Pain"},{"key":"10.1016\/j.cct.2022.106900_bb0085","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/ard.37.4.378","article-title":"Studies with pain rating scales","volume":"37","author":"Downie","year":"1978","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cct.2022.106900_bb0090","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.cct.2022.106900_bb0095","article-title":"Lilly reports robust third-quarter 2021 financial results as pipeline success strenghtens future growth potential","author":"Eli Lilly and Co.","year":"2021","journal-title":"Press release"},{"key":"10.1016\/j.cct.2022.106900_bb0100","article-title":"Pfizer Reports Third-Quarter 2021 Results","author":"Pfizer Inc.","year":"2021","journal-title":"Press release"},{"key":"10.1016\/j.cct.2022.106900_bb0105","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1212\/01.wnl.0000435747.02780.bf","article-title":"Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials","volume":"81","author":"Wolters","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.cct.2022.106900_bb0110","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1212\/WNL.0000000000002927","article-title":"Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials","volume":"87","author":"Wolters","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.cct.2022.106900_bb0115","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.pain.2013.03.006","article-title":"Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain","volume":"154","author":"Kivitz","year":"2013","journal-title":"Pain"},{"key":"10.1016\/j.cct.2022.106900_bb0120","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/annrheumdis-2013-204905","article-title":"Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain","volume":"74","author":"Schnitzer","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cct.2022.106900_bb0125","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1097\/j.pain.0000000000000211","article-title":"Efficacy and safety of tanezumab in the treatment of pain from bone metastases","volume":"156","author":"Sopata","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.cct.2022.106900_bb0130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/ajmg.a.35760","article-title":"Update from the 2011 international Schwannomatosis workshop: from genetics to diagnostic criteria","volume":"161A","author":"Plotkin","year":"2013","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.cct.2022.106900_bb0135","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13063-017-2413-6","article-title":"Development of a framework to improve the process of recruitment to randomised controlled trials (RCTs): the SEAR (screened, eligible, approached, randomised) framework","volume":"19","author":"Wilson","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.cct.2022.106900_bb0140","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-pharmtox-010818-021542","article-title":"The placebo effect in pain therapies","volume":"59","author":"Colloca","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.cct.2022.106900_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035711","article-title":"Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis","volume":"7","author":"Plotkin","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cct.2022.106900_bb0150","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1148\/radiol.2503080700","article-title":"Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images","volume":"250","author":"Cai","year":"2009","journal-title":"Radiology"},{"key":"10.1016\/j.cct.2022.106900_bb0155","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S1470-2045(10)70294-1","article-title":"International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer","volume":"12","author":"Wefel","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cct.2022.106900_bb0160","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0002-8703(03)00507-6","article-title":"Hypertensive patients\u2019 willingness to participate in placebo-controlled trials: implications for recruitment efficiency","volume":"146","author":"Halpern","year":"2003","journal-title":"Am. Heart J."},{"key":"10.1016\/j.cct.2022.106900_bb0165","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.318.7191.1114","article-title":"Is recruitment more difficult with a placebo arm in randomised controlled trials? A quasirandomised, interview based study","volume":"318","author":"Welton","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.cct.2022.106900_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113654","article-title":"The definition of placebo in the informed consent forms of clinical trials","volume":"9","author":"Hernandez","year":"2014","journal-title":"PLoS One"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714422002269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714422002269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:57:09Z","timestamp":1761555429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714422002269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":34,"alternative-id":["S1551714422002269"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2022.106900","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design of a randomized, placebo-controlled, phase 2 study evaluating the safety and efficacy of tanezumab for treatment of schwannomatosis-related pain","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2022.106900","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106900"}}